JP2024539520A5 - - Google Patents

Info

Publication number
JP2024539520A5
JP2024539520A5 JP2024548682A JP2024548682A JP2024539520A5 JP 2024539520 A5 JP2024539520 A5 JP 2024539520A5 JP 2024548682 A JP2024548682 A JP 2024548682A JP 2024548682 A JP2024548682 A JP 2024548682A JP 2024539520 A5 JP2024539520 A5 JP 2024539520A5
Authority
JP
Japan
Prior art keywords
approximately
months
immunogenic composition
dose
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078665 external-priority patent/WO2023076907A1/en
Publication of JP2024539520A publication Critical patent/JP2024539520A/ja
Publication of JP2024539520A5 publication Critical patent/JP2024539520A5/ja
Pending legal-status Critical Current

Links

JP2024548682A 2021-10-25 2022-10-25 マラリアワクチン製剤 Pending JP2024539520A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163271420P 2021-10-25 2021-10-25
US63/271,420 2021-10-25
US202163281332P 2021-11-19 2021-11-19
US63/281,332 2021-11-19
PCT/US2022/078665 WO2023076907A1 (en) 2021-10-25 2022-10-25 Malaria vaccine formulations

Publications (2)

Publication Number Publication Date
JP2024539520A JP2024539520A (ja) 2024-10-28
JP2024539520A5 true JP2024539520A5 (cg-RX-API-DMAC7.html) 2025-09-26

Family

ID=86158498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548682A Pending JP2024539520A (ja) 2021-10-25 2022-10-25 マラリアワクチン製剤

Country Status (6)

Country Link
US (1) US20240415947A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422676A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539520A (cg-RX-API-DMAC7.html)
KR (1) KR20240099337A (cg-RX-API-DMAC7.html)
AU (1) AU2022379612A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023076907A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTIPLE VACCINE VACCINATE AGAINST MALARIA TO CREATE LONG-TERM IMMUNE RESPONSE AGAINST PLASMODIA
WO2014111733A1 (en) * 2013-01-21 2014-07-24 Isis Innovation Limited Composition and uses thereof
WO2019021013A1 (en) * 2017-07-27 2019-01-31 Oxford University Innovation Limited ANTIMALARIAL VACCINE
AU2019410737A1 (en) * 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines

Similar Documents

Publication Publication Date Title
US8216595B2 (en) Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant
CA2138997C (en) Vaccine composition containing adjuvants
US20080063649A1 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
JP2016128513A5 (cg-RX-API-DMAC7.html)
EP0957933B1 (en) Vaccine composition against malaria
US11759517B2 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
JP2015524802A5 (cg-RX-API-DMAC7.html)
JP2011525169A (ja) Toll様受容体3の選択的アゴニスト
Hussein et al. Nanotechnology-based vaccines
JP2023012539A (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
KR102292147B1 (ko) 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
CA1323302C (en) Vaccine enhanced by interferon
PH12020500194A1 (en) Malaria vaccine
Ranjha et al. Rethinking malaria vaccines: perspectives on currently approved malaria vaccines in India’s path to elimination
US7550150B2 (en) Methods of treating or preventing a disease, disorder or condition associated with a viral infection
EP2723374B1 (de) Rekombinantes mistellektin und dessen verwendung als adjuvans
CN106163554B (zh) 一种包含pika佐剂的狂犬病组合物
EP4702988A1 (en) Combination product for the treatment of leishmaniasis
CN1270772C (zh) 抗乙型肝炎病毒治疗性疫苗及其佐剂
WO2003026686A1 (en) Potentiating the therapeutic effects of interferons
IE914250A1 (en) Use of interferon and a substance with an antimalarial¹activity for the treatment of malaria infections
HK40092095B (en) Pharmaceutical combined formulation for prevention or treatment of chronic hepatitis b, use thereof and combined formulation kit containing the same
Mismetti et al. Thromboprophylaxis in acute medical patients: need for an implementation strategy
CN1424110A (zh) 抗乙型肝炎病毒治疗性疫苗佐剂